NEUROENE THERAPEUTICS
Neuroene Therapeutics is a startup biotechnology company developing novel Vitamin K-based therapeutics for neurological disorders such as epilepsy. The company originated from collaborative research between Medical University of South Carolina investigators C. James Chou, Ph.D., and Sherine Chan, Ph.D., who cofounded and continue to lead Neuroene Therapeutics.
NEUROENE THERAPEUTICS
Industry:
Biotechnology Therapeutics
Founded:
2015-01-01
Address:
Mount Pleasant, South Carolina, United States
Country:
United States
Website Url:
http://www.neuroenetherapeutics.com
Total Employee:
11+
Status:
Active
Email Addresses:
[email protected]
Total Funding:
2.7 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Font Awesome Wordpress Plugins
Current Employees Featured
Founder
Investors List
Small Business Innovation Research
Small Business Innovation Research investment in Grant - Neuroene Therapeutics
PipelBiz.com
PipelBiz.com investment in Equity Crowdfunding - Neuroene Therapeutics
National Institutes of Health
National Institutes of Health investment in Grant - Neuroene Therapeutics
Official Site Inspections
http://www.neuroenetherapeutics.com Semrush global rank: 5.4 M Semrush visits lastest month: 1.56 K
- Host name: 104.21.54.115
- IP address: 104.21.54.115
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Neuroene Therapeutics"
Neuroene Therapeutics – Neurological Disease Treatment
Patented treatment for several disease indications including epilepsy, Parkinson’s, and rare mitochondrial disorders. Proprietary VK analogs are orally bioavailable, well tolerated, have …See details»
Who We Are – Neuroene Therapeutics
Neuroene Therapeutics was formed after our co-founders discovered a new class of compounds to improve mitochondrial health in multiple animal models of difficult-to-treat neurological diseases.See details»
Neuroene Therapeutics | LinkedIn
Developing mitochondrial small molecule drugs for difficult to treat neurological diseases. We are thrilled to announce that our compound, NT102, has received FDA Rare Pediatric Disease...See details»
MitoWorld
Neuroene Therapeutics’ portfolio includes issued and pending patents covering hundreds of analogs aimed at the treatment of numerous disease indications and the corresponding …See details»
Neuroene Therapeutics Company Profile | Management and
Founded in 2015, Neuroene Therapeutics is a biotech company focused on discovering, developing, and commercializing novel therapeutics for difficult-to-treat neurological disorders.See details»
Contact – Neuroene Therapeutics
Let’s talk about what’s next. Thank you for your interest in Neuroene Therapeutics. We are happy to answer any questions you may have about our innovative solutions. A Neuroene team …See details»
Neuroene Therapeutics, LLC - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Neuroene Therapeutics, LLC of Sunnyvale, CA. Get the latest business insights from Dun & Bradstreet.See details»
Neuroene Therapeutics Announces Orphan Drug Designation …
CHARLESTON, S.C., Oct. 29, 2021 /PRNewswire/ -- Neuroene Therapeutics announced that the FDA has granted orphan drug designation for the company's proprietary compound: NT102.See details»
Neuroene Therapeutics Announces Orphan Drug Designation
Nov 1, 2021 · CHARLESTON, S.C. – Neuroene Therapeutics announced that the FDA has granted orphan drug designation for the company’s proprietary compound: NT102. NT102 was …See details»
Neuroene Therapeutics Announces Orphan Drug Designation
CHARLESTON, S.C., Oct. 29, 2021 /PRNewswire/ -- Neuroene Therapeutics announced that the FDA has granted orphan drug designation for the company’s proprietary compound: NT102.See details»
Neuroene Therapeutics awarded $1.5 million to - EurekAlert!
Oct 29, 2018 · Neuroene Therapeutics, a start-up company founded by mitochondrial biologist Sherine S. L. Chan, Ph.D. and medicinal chemist C. James Chou, Ph.D. of the Medical …See details»
University of Toronto Entrepreneurship | ECHO Lessons from …
Please join us for an ECHO webinar featuring Dr. Sherine Chan, who will provide an overview of Neuroene Therapeutics, its technologies and the story behind its success. Neuroene …See details»
Neuroene Therapeutics awarded $225,000 STTR r | EurekAlert!
Aug 25, 2016 · Neuroene Therapeutics is using the Phase I STTR grant to help further develop a novel class of compounds for treating epilepsy. In the U.S. alone, epilepsy's estimated direct …See details»
Neuroene Therapeutics Receives NIH SBIR Award for Novel …
Neuroene Therapeutics has been awarded a Small Business Innovation Research (SBIR) grant by the National Institutes of Health (NIH). The award supports Neuroene’s ongoing research …See details»
Neuroene Therapeutics - BIO International Convention 2024
Jun 5, 2024 · Neuroene is developing mitochondrial-protective small molecules for epilepsy, Parkinson's and mitochondrial diseases.See details»
Neuroene Therapeutics - Overview, News & Similar companies
View Neuroene Therapeutics (www.neuroenetherapeutics.com) location in South Carolina, United States , revenue, industry and description. Find related and similar companies as well as …See details»
Neuroene Therapeutics - Craft
Neuroene Therapeutics has 2 employees across 2 locations. See insights on Neuroene Therapeutics including office locations, competitors, revenue, financials, executives, …See details»
Neuroene Therapeutics Directory – Maryland Tech Council
Neuroene Therapeutics is developing small molecule drugs for difficult to treat neurological diseases such as pharmacoresistant epilepsies and those induced by nerve agent exposure, …See details»
Pipeline – Neuroene Therapeutics
Progress is everything. Neuroene Therapeutics is working to develop potentially transformative therapies for patients and their families living with serious rare diseases. Medication-resistant …See details»
New vitamin K-based drug shows promise agains | EurekAlert!
Jul 6, 2020 · Researchers at the Medical University of South Carolina have formulated a vitamin K-based compound that, due to its unique structure and mechanism, eliminates medication …See details»